Incyte公司的培美替尼怎么购买？

Take by mouth, usually once daily during the first 14 days of a 21-day cycle, with or without food. Pemetinib belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps stop or slow the spread of cancer cells. So, how to buy Incyte’s pemetinib?

According to Medical Companion Travel, we have learned that the price of pemetinib is not fixed due to exchange rate fluctuations. For specific prices, you can consult the Medical Companion Travel Service. Patients in need can purchase the drug abroad or obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel), and have it shipped directly to their homes to ensure authenticity.

The FDA has accelerated the approval of the marketing application of the targeted drug pemetinib for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. As the first targeted drug for cholangiocarcinoma, pemetinib is expected to change the clinical treatment landscape for patients with cholangiocarcinoma.

American genetic engineering technology company, referred to as Genentech (Incyte), is the oldest biotechnology company in the United States and is currently the second largest biotechnology company in the world after Amgen in terms of scale and strength. In order to achieve the goal of becoming the world's largest oncology pharmaceutical company, Genentech suspended research on the long-acting recombinant human growth hormone Nutroppin Deptot and focused on the research and development of oncology drugs such as Avastin. Genentech is the earliest biotechnology pharmaceutical company established and the first to develop biotechnology drugs.

Pemetinib is a small molecule kinase inhibitor targeting FGFR1, 2 and 3 with an IC50 value of less than 2nM. Pemetinib also inhibits FGFR4 in vitro at approximately 100-fold higher concentrations than FGFR1, 2, and 3. Pemetinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability.

The most common adverse reactions are hyperphosphatemia, alopecia, diarrhea, dyspepsia, nausea, constipation, nail toxicity, fatigue, stomatitis, dry eye, dry mouth, loss of appetite, abdominal pain, hypophosphatemia, vomiting, arthralgia, back pain, and dry skin.

Recommended related hot articles: /newsDetail/96527.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.